



Patient Name	Gender	DOB	Phone
Address		Medicare #	Pension #

DIAGNOSTIC REQUEST – Diagnostic Services Requested

Please tick one only (Medicare criteria on reverse) ☐ PET only – Diagnostic CT not required

Medicare Eligible PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV contrast for the following indication:

- |  |                         |
|--|-------------------------|
| <input type="checkbox"/> BREAST CANCER, Stage III  | (61524 + 56807 + 56001) |
| <input type="checkbox"/> BREAST CANCER, suspected metastatic or recurrent                    | (61525 + 56807 + 56001) |
| <input type="checkbox"/> SOLITARY PULMONARY NODULE   | (61523 + 56807 + 56001) |
| <input type="checkbox"/> NON-SMALL CELL LUNG CANCER, staging                                 | (61529 + 56807 + 56001) |
| <input type="checkbox"/> HL or NHL, initial staging  | (61620 + 56807 + 56001) |
| <input type="checkbox"/> HL or NHL, assess response to first line therapy                    | (61622 + 56807 + 56001) |
| <input type="checkbox"/> HL or NHL, restaging  | (61628 + 56807 + 56001) |
| <input type="checkbox"/> HL or NHL, assess response to second line chemo                     | (61632 + 56807 + 56001) |
| <input type="checkbox"/> HEAD and NECK CANCER, staging                                       | (61598 + 56807 + 56001) |
| <input type="checkbox"/> HEAD and NECK CANCER, suspected residual cancer                     | (61604 + 56807 + 56001) |
| <input type="checkbox"/> METASTATIC SCC  | (61610 + 56807 + 56001) |
| <input type="checkbox"/> MELANOMA  | (61553 + 56807 + 56001) |
| <input type="checkbox"/> COLORECTAL CARCINOMA  | (61541 + 56807 + 56001) |
| <input type="checkbox"/> OESOPHAGEAL or GEJ CARCINOMA  | (61577 + 56807 + 56001) |
| <input type="checkbox"/> OVARIAN CARCINOMA   | (61565 + 56807 + 56001) |
| <input type="checkbox"/> UTERINE CERVIX CARCINOMA, primary staging                           | (61571 + 56807 + 56001) |
| <input type="checkbox"/> UTERINE CERVIX CARCINOMA, recurrent cancer for staging              | (61575 + 56807 + 56001) |
| <input type="checkbox"/> SARCOMA, initial staging  | (61640 + 56807 + 56001) |
| <input type="checkbox"/> SARCOMA, suspected residual or recurrent                            | (61646 + 56807 + 56001) |
| <input type="checkbox"/> <sup>68</sup> Ga - DOTA for evaluation of NETs                      | (61647 + 56807 + 56001) |
| <input type="checkbox"/> <sup>68</sup> Ga - PSMA, initial staging of prostate adenocarcinoma | (61563 + 56807 + 56001) |
| <input type="checkbox"/> <sup>68</sup> Ga - PSMA, restaging of prostate adenocarcinoma       | (61564 + 56807 + 56001) |

Medicare Eligible FDG PET Examination with Diagnostic CT Brain for the following indication:

- |   |                          |
|---|--------------------------|
| <input type="checkbox"/> ALZHEIMER'S DISEASE                                      | (61560 + 56001 or 56007) |
| <input type="checkbox"/> MALIGNANT BRAIN TUMOUR                                   | (61538 + 56001 or 56007) |
| <input type="checkbox"/> REFRACTORY EPILEPSY which is being evaluated for surgery | (61559 + 56001 or 56007) |

Other PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV Contrast for the following indication:

- |  |                   |
|--|-------------------|
| <input type="checkbox"/> <sup>68</sup> Ga - PSMA for evaluation of prostate adenocarcinoma | (+ 56807 + 56001) |
| <input type="checkbox"/> <sup>68</sup> Ga - DOTA for evaluation of NETs                    | (+ 56807 + 56001) |
| <input type="checkbox"/> Any other UNFUNDED PET  | (+ 56807 + 56001) |

Please advise if the patient is: ☐ Diabetic | ☐ Renal Function Impaired | ☐ Pregnant | ☐ Breastfeeding | ☐ Infection Precaution

☐ Consultation at time of examination requested with doctor: .....

Referral Details – Reason for Referral and Clinical History

Primary Disease Site:.....  
Histopathology:.....  
Surgery Type:.....  
Chemotherapy: Last:.....Next:.....  
Radiotherapy: Last:.....Next:.....  
Previous PET Scan: Y / N Location:.....

REQUESTING PRACTITIONER

Practitioner name, provider number, address, phone, fax

Practitioner signature and date

RESULTS

☐ EMERGENCY | ☐ Film | ☐ Phone | ☐ Fax .....am/pm | No .....  
☐ Copy reports to: .....



For appointments please phone:

1300 788 508

Garran  
Brindabella Specialist Centre  
5 Dann Close  
Fax: 6203 2111

Date ..... Time ..... Preparation .....

**PLEASE BRING RELEVANT  
FILMS AND IMAGES TO  
YOUR APPOINTMENT.**

Some examinations require special preparations, please check when making your appointment. Your practitioner has recommended that you use CIG. You may choose another provider but please check with your practitioner first.

## Referring for PET/CT

**Medicare Eligible PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV contrast for the following indication:**

- ☐ BREAST CANCER, Stage III, Whole body FDG PET study performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy. (61524 + 56807 + 56001)
- ☐ BREAST CANCER, Whole body FDG PET study performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy. (61525 + 56807 + 56001)
- ☐ SOLITARY PULMONARY NODULE evaluation, Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed. (61523 + 56807 + 56001)
- ☐ NON-SMALL CELL LUNG CANCER, Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned. (61529 + 56807 + 56001)
- ☐ HL or NHL, Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma. (61620 + 56807 + 56001)
- ☐ HL or NHL, Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma. (61622 + 56807 + 56001)
- ☐ HL or NHL, Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma. (61628 + 56807 + 56001)
- ☐ HL or NHL, Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma. (61632 + 56807 + 56001)
- ☐ HEAD and NECK CANCER, Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer. (61598 + 56807 + 56001)
- ☐ HEAD and NECK CANCER, Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy. (61604 + 56807 + 56001)
- ☐ METASTATIC SCC, Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes. (61610 + 56807 + 56001)
- ☐ MELANOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy. (61553 + 56807 + 56001)
- ☐ COLORECTAL CARCINOMA, Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy. (61541 + 56807 + 56001)
- ☐ OESOPHAGEAL or GEJ CARCINOMA, Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy. (61577 + 56807 + 56001)
- ☐ OVARIAN CARCINOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (61565 + 56807 + 56001)
- ☐ UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (61571 + 56807 + 56001)
- ☐ UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. (61575 + 56807 + 56001)
- ☐ SARCOMA, Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. (61640 + 56807 + 56001)
- ☐ SARCOMA, Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. (61646 + 56807 + 56001)
- ☐ <sup>68</sup>Ga - DOTA, Whole body PET study if:
  - a) a gastro-entero-pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or
  - b) both (i) a surgical amenable gastro-entero-pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and (ii) the study is for excluding additional disease sites.(61647 + 56807 + 56001)
- ☐ <sup>68</sup>Ga - PSMA, Whole body PSMA PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. Medicare benefits are payable for a maximum of one service in the patient's lifetime. (61563+56807+56001)
- ☐ <sup>68</sup>Ga - PSMA, Whole body PSMA PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who has undergone prior locoregional therapy and is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation. This item can be claimed by patients with a prostate specific antigen (PSA) increase of 2ng/ml above the nadir after radiation therapy; or failure of PSA levels to fall to undetectable levels; or rising PSA serum after a radical prostatectomy. Medicare benefits are payable for a maximum of two services in the patient's lifetime. (61564+56807+56001)

**Medicare Eligible FDG PET Examination with Diagnostic CT Brain for the following indication:**

- ☐ ALZHEIMER'S DISEASE, FDG PET study of the brain, performed for the diagnosis of (61560 + 56001), if:
  - (a) clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and
  - (b) the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and
  - (c) a service to which this item applies has not been performed on the patient in the previous 12 months; and
  - (d) a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer's diseaseApplicable not more than 3 times per lifetime (61560 + 56001 or 56007)
- ☐ MALIGNANT BRAIN TUMOUR, FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (61538 + 56001 or 56007)
- ☐ REFRACTORY EPILEPSY, FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery. (61559 + 56001 or 56007)

**Other PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV Contrast for the following indication:**

- ☐ <sup>68</sup>Ga - PSMA for evaluation of prostate adenocarcinoma (+ 56807 + 56001)
- ☐ <sup>68</sup>Ga - DOTA for evaluation of NETs (+ 56807 + 56001)
- ☐ Any other UNFUNDED PET scan (+ 56807 + 56001)

## Privacy Policy

For information on how we collect, use and disclose your personal information, please refer to our privacy policy at [www.canberraimaging.com.au/privacy-policy](http://www.canberraimaging.com.au/privacy-policy).